Hookipa Pharma SEC Filings

Welcome to our dedicated page for Hookipa Pharma SEC filings (Ticker: HOOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The HOOKIPA Pharma Inc. (HOOK) SEC filings page on Stock Titan aggregates the company’s U.S. regulatory documents, offering a structured view of key events in its history as a listed clinical-stage biopharmaceutical company. HOOKIPA’s filings trace the evolution of a business focused on next generation immunotherapeutics based on a proprietary arenavirus platform, with programs in oncology and serious infectious diseases, including collaborations with Gilead Sciences, Inc. for hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1).

For this issuer, several filing types are particularly important. Current reports on Form 8-K capture material events, such as the July 29, 2025 filing that discloses the results of a special meeting of stockholders. In that 8-K, HOOKIPA reports stockholder approval of the sale of certain assets to Gilead under an asset purchase agreement, approval of the liquidation and dissolution of the company and the related plan of dissolution, and approval of a proposal to permit adjournments of the special meeting if necessary. This filing provides formal confirmation of the company’s transition toward winding up.

Filings related to trading status and reporting obligations are also central for HOOKIPA. On July 29, 2025, the company filed a Form 25 to remove its common stock from listing and registration on the Nasdaq Capital Market, relying on the rule provision for voluntary withdrawal of a class of securities from listing and registration. On August 8, 2025, HOOKIPA filed a Form 15 to terminate the registration of its common stock under Section 12(g) of the Securities Exchange Act of 1934 and to suspend its duty to file reports under Sections 13 and 15(d). The Form 15 identifies the rule provisions relied upon and discloses the approximate number of holders of record at the certification date.

Earlier periodic reports such as Forms 10-K and 10-Q (referenced in the company’s press releases) provide broader context on HOOKIPA’s clinical-stage pipeline, collaboration arrangements, and risk factors, while Forms 3, 4 and 5 referenced in the company’s disclosures document insider holdings and transactions over time. On Stock Titan, these filings are updated from the SEC’s EDGAR system and are paired with AI-powered summaries that explain the significance of documents such as 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and specialized forms like Form 25 and Form 15. This helps readers quickly understand how HOOKIPA’s filings reflect its shift from an actively reporting Nasdaq-listed issuer to a company that has completed an asset sale, obtained approval for dissolution, delisted its shares, and moved to suspend its Exchange Act reporting obligations.